Abstract: Solid cannabidivarin, crystalline cannabidivarin, (R,R)-(?)-crystalline cannabidivarin, (S,S)-(+)-crystalline cannabidivarin and substantially pure forms thereof are disclosed herein. Further disclosed are methods of making such cannabidivarin, compositions and formulations comprising such cannabidivarin, and methods of treating disease with such cannabidivarin.

Abstract: Crystalline Cannabidiol of a novel form, including (R,R)-(?)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.

Abstract: The production of solvents for applications such as heat transfer, cleaning, and degreasing, for example. In particular, the production of solvents derived from 1-chloro-3,3,3-trifluoro-propene, such as chloro and/or fluoro substituted alkanes and chloro and/or fluoro substituted trifluoropropenyl ethers.

Abstract: Novel singly protected 2,2?-dihydroxybiaryls, electrochemical process for preparation of singly protected 2,2?-dihydroxybiaryls.

Abstract: A method produces acetic acid and includes a reaction step, a first purification step, a second purification step, and a third purification step. In the reaction step, a material mixture including methanol, carbon monoxide, a catalyst, and an iodide is subjected to a methanol carbonylation reaction in a reactor (1) to form acetic acid. In the first purification step, a crude acetic acid stream including acetic acid formed in the reaction step is subjected to distillation in a distillation column (3) to give a first acetic acid stream enriched with acetic acid. In the second purification step, the first acetic acid stream is subjected to distillation in a distillation column (5) to give a second acetic acid stream further enriched with acetic acid. In the third purification step, an acetic acid stream is subjected to purification in an additional purification unit (e.g.

Abstract: A process for producing an acetic acid product having low butyl acetate content via a carbonylation reaction. The carbonylation reaction is carried out at a temperature from 100 to 300° C., a hydrogen partial pressure from 0.3 to 2 atm, and a metal catalyst concentration from 100 to 3000 wppm, based on the weight of the reaction medium. The butyl acetate concentration in the acetic acid product may be controlled by removing acetaldehyde from a stream derived from the reaction medium and/or by adjusting at least one of reaction temperature, hydrogen partial pressure, and metal catalyst concentration.

Abstract: Processes for producing an ?,?-unsaturated carboxylic acid, such as acrylic acid, or a salt thereof, using solid promoters are disclosed. The solid promoters can be certain solid oxides, mixed oxides, and clays, illustrative examples of which can include alumina, zirconia, magnesia, magnesium aluminate, sepiolite, and similar materials.

Abstract: The present invention concerns a method of oxidizing a cycloalkane to form a product mixture containing a corresponding alcohol and ketone, said method comprising contacting a cycloalkane with a hydroperoxide compound in the presence of a catalytic effective amount of a cerium oxide based catalyst.

Abstract: A method for separation of fatty acid from a mixture having fatty acid, the corresponding acyl lactylate and lactic acid, method having steps of: a) providing dispersion of mixture in polar carrier; b) adjusting dispersion mixture to pH from 5-9; and, c) extracting fatty acid from dispersion carrier mixture into solvent immiscible with polar carrier, obtaining fatty acid solution and aqueous raffinate having lactic acid and fatty acid lactylate. Polar carrier has from 70-100 wt. % of water and from 0-30 wt. % of one or more miscible, polar co-solvents. Aqueous raffinate may be further processed by: i) acidifying raffinate to pH from 0-3; and, either ii)a) allowing acidified raffinate to separate into two layers and separating lower, aqueous layer from residual layer of acyl lactylate, or ii)b) extracting fatty acid lactylate from acidified raffinate into second solvent which is immiscible with aqueous raffinate, obtaining an acyl lactylate solution.

Abstract: The present invention relates to a process for producing ethyl esters of polyunsaturated fatty acids, comprising transesterifying triacylglycerols in extracted plant lipid.

Abstract: The present invention relates to a process for producing ethyl esters of polyunsaturated fatty acids, comprising transesterifying triacylglycerols in extracted plant lipid.

Abstract: The present invention relates to a process for producing ethyl esters of polyunsaturated fatty acids, comprising transesterifying triacylglycerols in extracted plant lipid.

Abstract: The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

Abstract: An apparatus for separating dimethyl carbonate using pervaporation includes: an atmospheric distillation column and a high pressure distillation column distilling a mixture containing dimethyl carbonate and methanol and separating dimethyl carbonate from the mixture; and a pervaporation membrane module disposed between the atmospheric distillation column and the high pressure distillation column and allowing for permeation of the methanol to separate the methanol from the mixture, thereby reducing heat consumption and a process cost as compared to the case of only using an existing pressure swing distillation method.

Abstract: Dibasic esters (diesters) and their use in plasticizer compositions are generally disclosed. In some embodiments, the diesters are branched-chain esters of long-chain alkanedioic acids, such as octadecanedioic acid. In some embodiments, such plasticizer compositions are used to increase the plasticity of a polymer resin, such as a vinyl chloride resin or poly vinyl butyral. In some other embodiments, such plasticizer compositions are used to lower the glass transition temperature of a polymer resin. In some embodiments, at least a portion of the plasticizer is derived from a renewable source, such as a natural oil.

Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L3 is a single bond, etc, R3 is alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.

Abstract: The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Abstract: The present invention discloses an improved process for preparing pure (6R)-6-(dimethylamino)-4,4-diphenyl-3-heptanone and its hydrochloride salt.

Abstract: This document describes a process for the high purity and high concentration recovery of monovalent products via continuous ion exchange from aqueous solution for further down-stream purification.

Abstract: A compound has Structure I: where R1 and R2 independently are C2-C12 alkyl groups, R3 and R3? independently are H or CH3, X1 is a C4-C28 alkyl or alkenyl group, and R4 is H or a N,N-bis((meth)acryloylalkyl)-amide group having Structure II: where R5 and R6 independently are C2-C12 alkyl groups, and R3? and R3?? independently are either H or CH3.

Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

Abstract: The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.

Abstract: The present invention relates to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer [in the formula, Y1 to Y8 are a chemical single bond, —O—, —O—C(?O)—, —C(?O)—O—, or the like; G1 and G2 are a divalent aliphatic group having 1 to 20 carbon atoms, or the like; Z1 and Z2 are an alkenyl group having 2 to 10 carbon atoms, or the like; A1 is a tetravalent aromatic group, or the like; A2 and A3 are a divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, or the like; A4 and A5 are a divalent aromatic group having 4 to 30 carbon atoms, or the like; Ax1 and Ax2 are an organic group having 2 to 30 carbon atoms that includes an aromatic ring, or the like; Ay1 and Ay2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; Q1 and Q2 are a hydrogen

Abstract: Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plasma ratio of 20:1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided.

Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a method for the production of urea allowing a substantial reduction, even down to zero, of the continuous emission of ammonia conventionally resulting from such a process. According to a preferred embodiment of the invention, the urea-forming reaction from carbon dioxide and ammonia is conducted in a synthesis section that does not require passivation by oxygen. As a result of the absence of oxygen, a hydrogen-rich gas stream results from the synthesis section, that can be used as a fuel in an incinerator. In the incinerator, ammonia-comprising gas streams from the urea production process are combusted.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Abstract: A method for producing a nitrogen-containing pentafluorosulfanylbenzene compound of formula (2a) or (2b): (wherein R1 a hydrogen atom or a hydrocarbon group; Z is an aryl group linked to a carbonyl group; Y is a group of formula (Y1), (Y2), (Y3), or (Y4); R2 is a hydrogen atom or a hydrocarbon group) the method comprising reacting a halogeno-pentafluorosulfanylbenzene compound of formula (1) with a nitrogenous nucleophile: (wherein X is a halogen atom; n is an integer of 1 to 5; R1 is as defined above).

Abstract: A binding pair for chromatographic separation or purification of a molecule of interest, where one binding member of the pair is an isomerizable organic molecule and the other binding member of the pair is an isomer-specific affinity agent bound to a molecule of interest. The binding pair associates and disassociates upon exposure to a binding agent, such as using light, decreased intensity of light, darkness, heat, stress, ions, an isomerizable affinity agent, change in pH, or a combination thereof.

Abstract: The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.

Abstract: The present invention addresses the problem of providing an inhibitor which has an excellent inhibitory activity on a p21-activated kinase. The present invention, by which has been solved the above-mentioned problem, is a p21-activated kinase 1 inhibitor containing, as an active ingredient, one or more compounds selected from the group consisting of dehydrokawain compounds, derivatives of dehydrokawain compounds, mimosine, derivatives of mimosine, and cucurbitacin compounds.

Abstract: 4-Amino-5-fluoro-3-chloro-6-(substituted)picolinates are prepared from trifluoroacetic acid, p-methoxyaniline, a 3,3-dialkoxyprop-1-yne and a substituted methylene amine by a series of steps.

Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a difluoromethyl-nicotinic indanyl carboxamide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g.

Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.

Abstract: Provided are inhibitors of Rho GTPase activation, and, in particular, compounds that inhibit RhoA activation by an RhoGEF. Also provided are related pharmaceutical compositions and methods. Also provided are methods of inhibiting Rho GTPase activation. Also provided are methods of screening for compounds that inhibit Rho GTPase activation by a RhoGEF.

Abstract: This invention relates to the use sigma-2 receptor antagonists, and of pharmaceutical compositions comprising such compounds, in methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology and more broadly treating with such compounds and compositions neurodegenerative diseases and disorders associated with Abeta pathology. This invention also relates to methods for screening compounds for activity in inhibiting cognitive decline on the basis of their ability to bind to a sigma-2 receptor.

Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Abstract: This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Abstract: Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.

Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: Methods and compositions are provided for synthesizing ionic liquids from lignin. Methods and compositions are also provided for treating lignin with ionic liquids.

Abstract: Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto.

Abstract: The present invention relates to a method of preparing chromanes from 2,5-dimethylfuran and substituted alkynes comprising an long chain unsaturated alkyl group as substituent in the alpha position of a substituted phenol followed by oxidation, reduction and acid ring closure. It is particularly advantageous to use 2,5-dimethylfuran as this offers an ecological beneficial synthesis of ?-tocopherol.

Abstract: A compound represented by the following formula (1): wherein each X independently represents an oxygen atom or a sulfur atom, or non-crosslinking, R1 represents a single bond or a 2n-valent group having 1 to 30 carbon atoms, the group may have an alicyclic hydrocarbon group, a double bond, a hetero atom, or an aryl group having 6 to 30 carbon atoms, each R2 independently represents a straight, branched or cyclic alkyl group having 1 to 10 carbon atoms, an aryl group having 6 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkoxy group having 1 to 30 carbon atoms, an aryloxy group having 6 to 30 carbon atoms, or a hydroxyl group, in which at least one R2 represents an alkoxy group having 1 to 30 carbon atoms or an aryloxy group having 6 to 30 carbon atoms, each m is independently an integer of 1 to 6, each p is independently 0 or 1, and n is an integer of 1 to 4.

Abstract: The disclosure relates to special orthoformic acid esters of formula (I), as defined herein, which can be used as thermally labile and acid-labile fragrance storage substances. The disclosure further relates to detergents and cleaning agents, cosmetic agents and air freshening products containing such orthoformic acid esters, as well as to a method for lastingly fragrancing surfaces.

Abstract: The present invention relates to the synthesis of alkoxy substituted benzaldehydes obtained from the corresponding alkoxy substituted benzenes. Alkoxy substituted benzaldehydes are products of broad commercial interest and are used as end products and intermediates in flavor and fragrance applications and pharmaceutical ingredients. For example, 3,4-methylendioxy-benzaldehyde (also known as heliotropin or piperonal) is used widely both as a end product and intermediate for the above mentioned applications. Other examples include 3,4-dimethoxybenzaldehyde, 3,4,5-trimethoxybenzaldehyde and 3,4-ethylenedioxybenzene which are intermediates in the synthesis of active pharmaceutical intermediates.